In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.

FCE 23762 is a new doxorubicin derivative obtained by appending a methoxymorpholinyl group at position 3' of the sugar moiety. The compound is greater than 80 times more potent than doxorubicin, it is highly lipophilic, and presents equivalent anti-tumour activity when administered by i.p., i.v...

Descripción completa

Detalles Bibliográficos
Autores principales: Ripamonti, M., Pezzoni, G., Pesenti, E., Pastori, A., Farao, M., Bargiotti, A., Suarato, A., Spreafico, F., Grandi, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977399/
https://www.ncbi.nlm.nih.gov/pubmed/1586598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977399/
https://www.ncbi.nlm.nih.gov/pubmed/1586598

Ejemplares similares